Sun Pharma announces US FDA approval for generic Gleevec®

Company eligible for 180-days marketing exclusivity on a first-to-file Para-IV ANDA

Mumbai, December 04, 2015: Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, Sun Pharma) today announced that one of its subsidiaries has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic version of Gleevec®, Imatinib Mesylate tablets 100mg and 400mg.

Imatinib Mesylate tablets, 100 mg and 400 mg are therapeutic equivalents of Novartis' Gleevec® tablets. As per IMS MAT August 2015, these tablets have annual sales of approximately US$ 2.5 billion in the US. These tablets are indicated for the treatment of chronic myeloid leukemia.

The Sun Pharma subsidiary, being the first-to-file an ANDA for generic Gleevec® with a para IV certification, is eligible for 180-days marketing exclusivity in the US. Under the terms of a settlement agreement with Novartis, the Sun Pharma subsidiary is permitted to launch its version of generic Gleevec® in the United States on February 1, 2016. The commercial launch of this product is scheduled for February 1, 2016.

Gleevec® is the registered trademark of Novartis Pharmaceuticals Corporation.
About Sun Pharmaceutical Industries Ltd. (CIN - L24230GJ1993PLC019050):
Sun Pharma is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable us to deliver quality products in a timely manner at affordable prices. It provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world. Sun Pharma's global presence is supported by 50 manufacturing facilities spread across 5 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities. The consolidated revenues for 12 months ending March 2015 are approximately US$ 4.5 billion, of which US contributes US$ 2.2 billion. In India, the company enjoys leadership across 13 different classes of doctors with 30 brands featuring amongst top 300 pharmaceutical brands in India. Its footprint across emerging markets covers over 100 markets and 6 markets in Western Europe. Its Global Consumer Healthcare business is ranked amongst Top 10 across 4 global markets. Its API business footprint is strengthened through 14 world class API manufacturing facilities across the globe. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising about 2,000 scientists and R&D investments of over 7% of annual revenues. For further information please visit www.sunpharma.com & follow us on Twitter @SunPharma_Live

 

You have received this email as your address is part of our Investor Relations and Media Contacts list.  All our Press Releases and Financial updates are sent to those on the list.
•        If you wish to be removed from this list or your address has been accidentally included here, then please let us know by a return email and we will remove it.  
       All the others will continue to be on the mailing list.
•        If you wish to receive emails on some other email id, please send it to us.
•        If you think that somebody else from your organisation should be added to this list, then please ask him / her to send us an email and we will add.
•        If you are changing jobs, please send us your new email id.  We would like to be in touch with you and keep you updated on happenings at Sun Pharma.

We would be happy to host one-on-one, group and telephone meetings for updates on the Company.  If you wish to setup such a meeting, feel free to get in touch with us.  In-person meetings can be at our office or elsewhere depending on mutual convenience.  Our contact details:
Nimish Desai
Tel : +91 22 4324 4324, Ext 2778
Tel Direct : +91 22 43242778
Mobile : +91 98203 30182
E mail: [email protected] Frederick Castro
Tel : +91 22 4324 4324, Ext 2777
Tel Direct : +91 22 43242777
Mobile : +91 99206 65176
E mail : [email protected]

 

Ajay Khodke
Manager
Investor Relations & Corp. Comm. 
Sun Pharmaceutical Industries Ltd
SUN HOUSE, 201 B/1, Western Express Highway,
Goregaon (East), Mumbai,
Maharashtra (India) – 400 063
Telephone: +91 22 4324 2779
Email: [email protected]
  www.sunpharma.com
Please consider the environment before printing this email

 

Information disclaimer: This email and any files transmitted with it are privileged and confidential and intended solely for the use of the individual or entity to whom they are addressed. If you are not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this email in error and you should not review, disseminate, distribute or copy this e-mail or any attachments contained herein. Please notify the sender immediately by e-mail and delete this e-mail from your system. E-mail transmission cannot be guaranteed to be secure or error-free as information could be intercepted, corrupted, lost, destroyed, arrive late or incomplete, or contain viruses. The sender therefore does not accept liability for any errors or omissions in the contents of this message, which arise as a result of e-mail transmission. The sender also confirms that it shall not be responsible if this email message is used for any indecent, unsolicited or illegal purposes, which are in violation of any existing laws and the same shall solely be the responsibility of misuser and that the sender shall at all times be indemnified of any civil and/ or criminal liabilities or consequences thereof. If verification is required please request a hard-copy version.

Suggested Articles

Merck is scouting replacements for CEO Ken Frazier with a preference toward an internal candidate, Bloomberg reports.

Bluebird Bio says the launch of Zynteglo, its first gene therapy, will not occur until 2020 while it tightens up its manufacturing processes.

Riival generics makers are squashing long-running lawsuits over their own versions of Sanofi's big-selling blood thinner Lovenox.